tirzepatide december 19 FDA Announces End To Compounded By March 19, 2025 The Holidays are here, now

Our providers will work with you to determine the optimal treatment length for your desired outcomes, helping you plan for the financial aspect of your journey

The change in body weight, fat mass, and lean mass from baseline to week 72 was 21.3 percent, 33.9 percent, and 10.9 percent respectively with tirzepatide

S., Umapathysivam, M

At the maximum dose of 15 mg, people in studies lost an average of 22.5% of their body weight over a 72-week period

Owing to its unique structure and mode of action, SS-31 demonstrates potential therapeutic value across cardiovascular diseases, neurodegenerative disorders, kidney injury, and myopathies associated with mitochondrial dysfunction 1-6

Important information This product is a compounded preparation and has not been evaluated or approved by the FDA